This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S). and BÜCHI Labortechnik AG, both leaders in cannabis production and processing services. About Valcon Medical.
Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.
On July 1, the process of procuring pharmaceutical-approved cannabis was simplified for individuals residing across the state, where the first licensed medical marijuana dispensary opened its doors in August 2020. The latest changes to Virginia’s medical cannabis law adds to a growing list of amendments aimed at improving patient access.
In general, I think that botanical medicine is safer than pharmaceutical medicine, that the chances of causing harm are much less. I include pharmaceutical drugs in that category. In general, I think that botanical medicine is safer than pharmaceutical medicine. They’re less interested in the pharmaceutical versions.
There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business. In Virginia, these families were simply asking to be able to possess the medicines they were able to access in other states. This interview has been edited for clarity and space. We need to do more.
He has guided clients on license applications, facility design and build out, equipment installation and optimization, and plant oil extraction for cannabis and hemp processing facilities. with unknown pharmacological and safety profiles.”
Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).
We are one of the first to successfully complete a commercial shipment of Colombian-manufactured high-CBD pharmaceutical product to Germany available for patients in pharmacies under prescription. In addition, this reflects our increasing know-how to comply with complex and sophisticated regulatory and quality frameworks.
1 SPINS’ CBD category typically includes sales of products that contain hemp-based CBD extracts, including CBD oils, gummies, and capsules. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022. Accessed October 17, 2022. Accessed October 17, 2022. 2021;56:530-543.
Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.
The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. GW is the world’s oldest and largest pharmaceutical company solely focused on producing medicines derived from cannabis plants, which it grows in Britain. By Nikitha Sattiraju.
Flora will now have the ability to quickly and efficiently reference and manage information at its cultivation and extraction facility, collect and analyze data, derive insights to find cost efficiencies, and ensure accuracy. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.
The company’s innovative technology enables the provision of an exact amount of active ingredients through oral ingestion, using a high concentration of cannabinoids or medical cannabis extract in a homogeneous, uniform and stable formulation which can be administered in the form of oral capsules, syrups or buccal sprays. Of Cannassure.
This is a strategic opportunity for us to reach the widest audience of customers possible while being the first and, at the moment, the only company with a permit to market cannabis extracts for inhalation in Germany specifically and in Europe in general.
So for now, we wait in anticipation for the DEA to commence proceedings to determine how to amend the scheduling of CBD under the CSA in a way that will allow for Epidiolex to be prescribed by health care providers and dispensed by pharmaceutical companies appropriately and legally.
Dr. Dadi Segal , Founder and CEO of Panaxia Israel : “We are excited to be the first and exclusive company in Europe to receive a marketing permit for inhaled medical cannabis extracts. It is a global pharma company, that develops, manufactures and markets advanced medical cannabis products of pharmaceutical high quality.
This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.
(ASX: LGP) (“LGP”), a vertically integrated cannabis manufacturer, that AMP has been appointed as marketer and distributor of LGP medical cannabis extracts to pharmacies and clinics in Germany , including exclusive distributor of LGP’s 20:5 LGP Classic and 10:10 LGP Classic extract oils. ” Ms.
.” Gottleib qualified this by saying that CBD access is not a straightforward issue because CBD has already been investigated and approved as a drug, Epiodiolex , which generally means CBD cannot be added to food. This is where things get interesting.
This new research has increased our hopes for an alternate CBD source, which may increase the availability of CBD-based products, reduce purchase costs, and guarantee THC-free extracts. Even more, CBD is the first FDA-approved pharmaceutical drug for two rare forms of epileptic seizures in kids.
As such, the company is creating a new standard in the industry by providing better and safer access to such cannabis medications. It develops high-quality medical cannabis extract formulas, medical device vaporisers, and other innovative delivery methods. Kanabo is an established leader in medical cannabis research and innovation.
With full government approval through Health Canada for exclusive access to a full cGMP-certified pharmaceutical manufacturing facility, Mydecine continues to advance the clinical progress in its 4 leading novel compounds, MYCO-001 through 004 with the ability to import or export, cultivate, extract or isolate, and analyze active mushroom compounds.
By uniting the strength of Open Book Extract’s quality innovation and custom product development with Radicle Science’s unbiased scientific rigor in natural products research, we can impact every stage of the product life cycle from ideation to validation. About Open Book Extracts. About Radicle Science. Headquartered in Roxboro, N.C.,
The brand’s growers are pharmaceutical experts who think of the user’s best needs every step of the way. The company has a wide range of products including strain-specific extracted oil, activated THC distillate, and specially-formulated cannabinoid medicine. MPX – Melting Point Extracts. Abx – AbsoluteXrracts.
Beis expressed his excitement about the factory being the largest pharmaceutical facility in Europe, where a medical cannabis industry is sprouting across Luxembourg, Germany, and Malta. “A M edicinal-grade cannabis will be cultivated inside a 25,000-square-foot extraction and processing facility as part of the Greek Kaya Project.
The acquisition by Ramm provides access to HemPoland’s distribution network, recognized premium brands, hemp oil extraction technologies, and an additional synergistic foothold into the European market following the acquisition of Sicily-based Canapar Corp. (CSE: TGOD) for cash consideration of C$1.2 HemPoland S.p.a.
Yes, you will be able to upload your records directly to your patient portal which you will receive access to. These oils are extracted by the licensed Pharmaceutical Processors that have been selected to grow, process, and dispense medical cannabis in Virginia. Do I Need to Present my Medical Records to Canna Care Docs?
Now, the latest trend among folks living in states without access to legal cannabis is THC-O. Legalization has helped mitigate some of these issues by increasing access to lab-tested cannabis, which identifies levels of cannabinoids and terpenes as well as dangerous/banned substances. At one time, it was all about THC. Then came CBD.
For now, if you have access to quality CBD products, there’s no reason to prioritize CBG products. Easy access. Another factor that increased CBD’s popularity was the FDA approval of an antiepileptic cannabis-based drug named Epidiolex — a highly concentrated CBD extraction mixed with sesame oil and some flavoring.
Following this selection, Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different degrees of THC and CBD for patients with varying medical conditions.
and RAD – are well recognized across the country and through GWNG we will benefit from speed-to-market in Quebec and consumers will have access to our high quality, fairly priced products.”. “Products across all of our brands – Pura Vida, Purefarma, Premium 5, feelgood., Follow Heritage’s Purefarma, Pura Vida, Premium 5, and feelgood.
Ultimately, beyond increased access, a big reason that seniors are turning to cannabis is that it helps with a range of health issues. Another important aspect for seniors is that medicinal cannabis users tend to take less pharmaceutical drugs. Accessed December 5 2018. Accessed December 5 2018. Let’s take a closer look.
Is it a natural response to the fact that recreational is supposedly on the way or a the report suggests it’s hard as a patient to access so therefore people are just giving up. The current lack of market growth reflects an unfortunate reality in Germany that patient access to medical cannabis is still quite low.
Clinical stage CBD company Botanix Pharmaceuticals (ASX: BDA ) works on using cannabidiol (CBD) in its treatment of skin conditions including acne, psoriasis, dermatitis and rosacea. Investing in cannabis stocks on the ASX: Investing in ASX cannabis stocks. Keep up with major deals and investment opportunities in marijuana.
Remember, the pharmaceutical model is “this medicine addresses this specific target.” There are pharmaceuticals for ADHD or behavioral issues, for example, which target this receptor. How easy is it to access CBG products? People often ask: How is it possible that these compounds can do so many things?
The Berlin-based company has a Fast Track Access platform that enables producers worldwide to become part of the German market and focuses on long-term collaborations and carries products such as dried flowers, extracts, Dronabinol and pharmaceutical-grade CBD. Miracle Valley’s operations are based in Mission, B.C.
If the proposal — which was sponsored by Rules Committee Chairman Bill Rabon (R) — is enacted into law, patients who are diagnosed with a “debilitating medical condition” could legally gain access to medical cannabis in North Carolina. Home cannabis cultivation, on the other hand, would be forbidden.
Kanabo’s proprietary medical cannabis extracts focus on sleep disorders and post-traumatic stress disorder, and are specially formulated for vaporization with the medically certified VapePod vaporizer platform. Accessible on any mobile device, the system’s dashboard provides full control over any grow operation from anywhere in the world.
Panaxia Israel has just imported from the US hemp extracts from which it will manufacture CBD-rich cannabis products. Essence extraction was conducted in a facility jointly operated by Panaxia and Ultra Health located in New Mexico , US. About Panaxia Israel. and constitutes the Group’s cannabis division.
We believe that Farmalabor’s extensive experience of the Italian pharmaceutical industry makes it the ideal partner to unlock the full potential of this local market.”. EMMAC is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production.
Cannabis is being viewed as a potential treatment for epileptic seizures and large success has been witnessed so far, triggering a large movement of people and organisations who are in favour of its access and medicinal use. ” CBD may be easier for patients to access when they opt to start treatment with medical cannabis.
The FDA recently approved a CBD-based drug to help treat childhood epilepsy such as Dravet’s Syndrome which is difficult to treat with conventional pharmaceuticals. Strains that focus on CBD extraction, such as Charlotte’s Web , have been bred to have low amounts of THC and high amounts of CBD. Products containing less than.3%
The Government Pharmaceutical Organization launched the first batch of medical CBD oil, THC oil, and CBD:THC oil (4,500 units of 5 milliliters each) for the special access scheme (SAS) in public hospitals. End of the “amnesty period,” during which persons possessing cannabis for certain purposes (medical, research, etc.)
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
86 
Let's personalize your content